Your session is about to expire
← Back to Search
VS-6063 + Chemotherapy for Ovarian Cancer
Study Summary
This trial will test the safety and efficacy of the combination of VS-6063, carboplatin, and paclitaxel in patients with ovarian cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My ovarian, fallopian tube, or peritoneal cancer is not responding to platinum-based chemotherapy.I am not on current cancer treatments and stopped any cancer-directed treatments at least 3 weeks ago.I have had 2 or fewer chemotherapy treatments for my recurring cancer.I am a woman who can have children, have a negative pregnancy test, and use birth control.I have been treated with drugs that target enzymes.My cancer is one of the specified types, like serous or clear cell adenocarcinoma.My ovarian, fallopian tube, or peritoneal cancer came back within 6 months after platinum chemotherapy.My bone marrow, kidneys, liver, and nervous system are functioning well.I have recovered from recent cancer treatments with no major side effects.I have had issues like bleeding or holes in my stomach or intestines.I stopped my hormone therapy for cancer at least a week ago.I have not been diagnosed with any cancer other than non-melanoma skin cancer in the past 5 years.I am not currently on antibiotics for an infection, except for a simple UTI.I have had one platinum-based chemotherapy treatment for my cancer.I have had one non-chemotherapy treatment for my recurring or persistent disease.
- Group 1: Defactinib (VS-6063) +Carboplatin/Paclitaxel
- Approved for 10 Other Conditions - This treatment demonstrated efficacy for 10 other conditions.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is access to this research project currently available for participants?
"Indeed, current information on clinicaltrials.gov specifies that this research is actively recruiting participants. The study was first published on February 6th 2018 and was last modified January 23rd 2020; the investigators are hoping to recruit 90 people at a single location."
What further investigations have been conducted regarding the effects of VS-6063?
"In total, 1182 studies are currently underway studying the therapeutic potential of VS-6063. Of those active investigations, 332 have progressed to Phase 3 and span 68069 locations with a majority located in Shanghai."
How extensive is the scope of this experimental program?
"Correct. According to clinicaltrials.gov, this medical trial is actively seeking participants from a single location and 90 people in total. The study was first posted on February 6th 2018 with the most recent update occurring January 23rd 2020."
What are the essential goals of this trial?
"The objectives of this 4 year trial are to gauge the safety and tolerability of VS-6063 plus paclitaxel and carboplatin chemotherapy (as evaluated through adverse events), observe changes in health related quality-of-life among patients receiving treatment, document any toxicities that may arise from therapy, and record overall survival rates as per RECIST 1.1 standards."
Share this study with friends
Copy Link
Messenger